Introduction
A group of directors from lung cancer patient advocacy organizations and key opinion leaders in the lung cancer field held a roundtable on March 13-14, 2018, in New York City to discuss trends in biomarker testing for patients with lung cancer.
The objective of this roundtable was to align on strategies to optimize patients' and physicians' awareness of biomarker testing to increase uptake in order to ensure all lung cancer patients receive the most effective treatment. Discussions from the roundtable led to the development of this whitepaper, which will be posted on the websites of the participating lung cancer advocacy groups and cancer organizations (Table 1) . Its goals are to highlight advances in lung cancer treatment due to the advent of targeted therapies, describe underutilization of biomarker testing in patients with advanced lung cancer, and develop an action plan to optimize the education of patients and physicians regarding biomarker testing.
An Overview of Biomarker Testing
In the past 10 years, major advances have been made in our understanding and treatment of lung cancer. Lung cancer is not just a single disease, but rather describes many different types of cancer that develop in the lung. The two main types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for ~ 85% of lung cancers and can be further classified as adenocarcinoma, squamous cell carcinoma, or large cell carcinoma based on the type of cell where the cancer starts. 1a Within these categories, many additional subtypes have now been identified based on unique genetic changes (or driver mutations) that allow a specific cancer to develop and grow.
These unique mutations serve as biomarkers that help doctors classify an individual's specific type of lung cancer and help determine the most appropriate treatment. biomarker. 1,3,6,7a Approved targeted therapies are also available for patients with lung adenocarcinoma who have ROS1 and BRAF mutations. 8,9b Immunotherapies that target PD-1 and PD-L1 (proteins that inhibit the immune system from attacking the cancer cells) also improve survival in patients with NSCLC and are approved for the treatment of patients with adenocarcinoma or squamous-cell NSCLC. 10-13c Drugs targeting a number of other biomarkers found in patients with NSCLC are being investigated in clinical trials.
Currently, there are no available targeted therapies for patients with SCLC.
However, several promising drugs are currently being tested in clinical trials for this disease. Additionally, the Lung Cancer Alliance conducted a needs assessment survey for the lung cancer community, the results of which further support lack of testing and testing awareness among lung cancer patients. 16 In the survey, 1 in 6 patients reported not knowing if they had received molecular testing.
Barriers to biomarker testing include lack of awareness among oncologists, pathologists, and pulmonologists regarding the importance of biomarker testing for treatment selection b and suboptimal tissue sampling to run the test. Finally, public policy initiatives include efforts to change the Date of Service/14-day rule requiring hospitals to pay for testing if done within 14 days of outpatient admission, which can delay testing. Advocating for coverage of next generation sequencing, a briefing on the importance of advanced diagnostics on Capitol Hill, and ongoing work to include biomarker testing as a quality metric are also being done.
Biomarker-Focused Educational Materials: An Audit of Gaps and Unmet Needs
In addition to the initiatives noted above, the LUNGevity foundation conducted an audit of educational materials on biomarker testing produced by industry and
advocacy groups that were geared toward patients and physicians. The goal of the audit was to identify gaps and unmet needs in educational efforts designed to increase awareness of biomarker testing.
The audit found wide variability in the language used to describe biomarker testing, both in materials from different advocacy organizations and between materials developed by industry and advocacy groups. Even the term "biomarker testing" itself is not uniformly used. Genetic testing, molecular testing, genetic diagnostics, molecular diagnostics, and molecular pathways (among others) are all currently used to describe biomarker testing in materials from different sources. This finding highlights the need to establish a common terminology to avoid confusing patients. To this end, organizations and industry that participated in the audit agreed on the term "biomarker testing" as a standardized term, given that the term "biomarker" includes testing for driver mutations as well as immunohistochemistry-based tests such as PD-L1.
A subsequent audit also looked at how well various educational materials from different sources covered key aspects in terms of the WHO, WHAT, WHEN, WHERE, WHY, and HOW of biomarker testing ( Likewise, patient-facing materials from industry were generally comprehensive in their coverage of WHY and WHO, and also did a good job describing HOW biomarker testing should be done. However, 50% or fewer of the patient-facing, industry-generated educational materials that were examined comprehensively described WHAT biomarker testing is and WHERE or WHEN it should be done.
Finally, the majority of physician-facing materials (developed by industry) 
Call to Action, Part 1: Develop Consensus Terminology and Messaging in Patient Educational Materials
The roundtable participants identified the lack of a unified message in patient educational materials as a barrier to effective patient education. Many lung cancer patients use multiple sources to obtain information about their diagnosis;
if the information across sources is varied, patients can become confused or overwhelmed. To address this issue, patient advocacy groups, healthcare providers, and industry need to align on common terminology and messaging with regard to biomarkers and other patient educational materials. To achieve this goal, two potential avenues were outlined that patient advocacy groups could act on.
Option 1: Common Messaging; Different Wrappers
Under this approach, patient advocacy groups would combine forces and work together to generate joint educational materials on biomarker testing. Each advocacy group involved in the collaboration would have a seat at the table in terms of developing the materials. In addition to a unified and cohesive message for patients, benefits of a common core set of educational materials include the ability to pool resources to save on costs (ie, medical writing, design, project management, honorarium for reviewers, printing), the potential to cost-effectively translate the materials into multiple languages, and the benefits of individuals with various expertise working together.
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Several possibilities were discussed in terms of how to package the educational content generated through this collaboration.
1. Common factsheets, brochures, and pamphlets could be generated with the logos of all collaborators included at the bottom. The presence of multiple logos was viewed as presenting a message of support and consensus among major advocacy organizations in the lung cancer arena.
2. The educational content could be created in collaboration, but each advocacy group would then package the information with their own branding. This approach would allow for each advocacy group to maintain a uniform look with all their educational materials.
3. A combination of the first 2 approaches could also be utilized (ie, a central, shared core fact sheet or pamphlet with individual organizations incorporating their own unique branding to additional materials to supplement the core materials).
Option 2: One Voice, Individual Identity
Under this approach, patient advocacy groups would work together to develop a shared consensus statement of best practices and common core items or "building blocks" for use by each organization to develop their own materials. The consensus materials would be developed in collaboration and would include agreed-upon terminology and definitions, aligned key messages, common numbers and facts, and checklists/questions for patients to ask their care team.
Standards for the best way to develop and organize educational materials based
on these "building blocks" would also be developed (eg, the order in which to present information, overall tone, and aiming for a sixth-grade reading level).
Educational materials developed based on the consensus statement could be identified with a unique tagline (eg, proud member of the Counsel of Cancer Education).
Many of the same benefits as Option 1 would also apply to this option (ie, uniform message, pooling expertise, potential to increase translation into different languages). In addition, this "building blocks" approach would allow organizations to maintain their autonomy and own identity by retaining a common agreed-upon terminology and message.
Common Messaging: Barriers, Solutions, and Strategies for Measuring Success
Both approaches described above present a paradigm shift in how educational materials are currently developed, requiring collaboration and agreement by patient advocacy groups and support from industry partners. Barriers to this approach include the fact that best practices for both nonprofits and for-profit corporations in terms of branding, marketing, and fundraising/development encourage each organization to create their own uniquely branded materials.
Moreover, despite a common goal among lung cancer advocacy organizations and the many ways that they partner together on other efforts, competition for funding from individuals and industry does exist.
For the collaborative development of common messaging and materials to be successful, a point of contact to drive the project (write grants, project 
Call to Action, Part 2: Understanding and Addressing Physician Knowledge Gaps
Physicians play a key role in both educating patients and ensuring their patients with advanced-stage NSCLC receive biomarker testing at diagnosis. As such, it is important that physicians and other healthcare providers are involved in the development of, and encouraged to use, the core messaging and terminology developed by patient advocacy groups and industry, as described in the previous section.
In addition, it is essential to understand physician-related barriers (eg, insufficient sample collection at biopsy, physicians not sending patient samples for biomarker testing) to timely and accurate biomarker testing. The first step in addressing this issue is to gain a fuller understanding of physicians' knowledge gaps and other reasons to explain why biomarker testing is not being performed. Society National Lung Cancer Roundtable meeting that will focus on physicians' knowledge gaps and development of a consensus statement on biomarkers for physicians is also encouraged to ensure uniformity across organizations and in messaging for patients and physicians.
